基因组无细胞DNA测序用于治疗毒症的监测
Research square
|January 9, 2026
概括
一种新的SIFT-seq试验通过使用无细胞DNA (cfDNA) 同时检测病原体和器官损伤来改善败血症诊断. 这种方法提高了准确性,即使在抗生素治疗后,也为重症监护提供了一个有前途的工具. 关键词:败血症诊断,cfDNA,SIFT-seq,病原体检测,器官损伤.
科学领域:
- 微生物学 微生物学
- 基因组学就是基因组学.
- 关键护理医学 关键护理医学
背景情况:
- 败血症是一种危及生命的疾病,需要早期识别病原体并评估器官损伤.
- 目前的诊断方法通常是有限的,特别是在开始抗生素治疗后.
- 无细胞DNA (cfDNA) 基因组学为同时进行病原体和起源组织分析提供了潜力,但面临着污染挑战.
研究的目的:
- 为了评估通过标记和测序 (SIFT-seq) 测试发现的样本内在微生物DNA,以诊断败血症.
- 评估SIFT-seq从cfDNA同时检测病原体和器官损伤的能力.
- 确定SIFT-seq是否改善诊断性能,特别是在接受抗生素的患者中.
主要方法:
- 分析了来自败血症患者,非败血症ICU对照和健康对照的142个血样本.
- 应用SIFT-seq试验来减少污染,并分析微生物DNA和宿主反应.
- 将SIFT-seq结果与血液培养结果进行比较,并与SOFA得分进行整合.
主要成果:
- SIFT-seq确定了与抗生素前血液培养良好一致的败血病原体.
- 该试验检测到毒症患者的免疫活性升高和器官损伤标志物.
- 结合SIFT-seq和SOFA得分的多变量模型在毒症诊断中获得了0.874的AUC.
结论:
- 在cfDNA分析中,SIFT-seq试验有效降低了污染.
- 使用SIFT-seq的综合cfDNA分析通过检测病原体和器官损伤来增强败血症诊断.
- 这种方法显示出改善败血症管理的巨大潜力,尤其是在抗生素治疗后.
相关概念视频
Pharmacogenomics: Identification of New Drug Targets
129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
Modern Molecular Taxonomy
865
Advancements in molecular biology have revolutionized the identification and characterization of bacteria, with multiple methods leveraging DNA sequencing for enhanced precision. As sequencing technologies improve and costs decline, these approaches are increasingly used in clinical, environmental, and evolutionary studies.Multilocus Sequence Typing (MLST) examines several housekeeping genes, essential chromosomal genes encoding cellular functions, to distinguish strains. Approximately...
865


